Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Omnicell, Inc.NASDAQ: OMCL
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $140.36M rose 26.5% year over year, ahead of the +8.5% change in trailing-twelve-month gross profit. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.
Context
- Gross profit amounted to 42.9% of revenue in FY2025, up 0.5 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +26.5% holds above the trailing-twelve-month pace of +8.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 508.04M USD
- Year-over-year change
- +7.9%
- 4-year CAGR
- -2.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 508.04M | +7.9% |
| FY2024 | 2024-12-31 | 471M | -5.8% |
| FY2023 | 2023-12-31 | 499.93M | -15.1% |
| FY2022 | 2022-12-31 | 588.99M | +6.2% |
| FY2021 | 2021-12-31 | 554.65M | — |
Gross Profit vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's LTM Mar 2026 gross profit of $532.87M is the 3rd highest of the 11 companies compared; the peer median is $324.11M.
- Its year-over-year change of +8.5% is the 6th highest of 11, against a peer median of +8.3%.
- Gross profit amounts to 43.5% of revenue for OMCL, versus a peer median of 62.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.65B | -8.3% | +1.9% | 65.6% | |
| LTM Mar 2026 | $681.98M | -8.9% | +1.8% | 86.6% | |
| LTM Mar 2026 | $532.87M | +8.5% | -4.8% | 43.5% | |
| LTM Sep 2026 | $444.65M | +0.6% | +3.9% | 71.9% | |
| LTM Mar 2026 | $328.47M | +19.9% | +14.0% | 9.3% | |
| LTM Apr 2026 | $326.13M | +10.3% | +23.9% | 65.8% | |
| LTM Jun 2026 | $322.09M | +16.1% | +22.1% | 24.6% | |
| LTM Mar 2026 | $187.61M | +60.4% | +58.7% | 66.2% | |
| LTM Jun 2026 | $180M | +6.3% | +23.6% | 28.5% | |
| LTM Sep 2026 | $157.53M | +5.4% | +12.2% | 58.5% | |
| LTM Mar 2026 | $23.44M | +226.7% | +241.8% | 48.4% | |
| Peer median (excluding OMCL) | $324.11M | +8.3% | +18.1% | 62.1% | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.3B | 1.15B | 1.11B | 1.18B |
| Cost of Revenue | 577.37M | 706.96M | 647.18M | 641.24M | 676.8M |
| Gross Profit | 554.65M | 588.99M | 499.93M | 471M | 508.04M |
| Gross Margin | 49.0% | 45.4% | 43.6% | 42.3% | 42.9% |
| Research & Development | 75.72M | 104.97M | 93.29M | 90.41M | 87.74M |
| Selling, General & Admin | 389.43M | 486.34M | 425.97M | 380.25M | 408.64M |
| Operating Expenses | 465.15M | 591.31M | 519.26M | 470.67M | 496.38M |
| Depreciation & Amortization | 84.93M | 99.17M | 95.56M | 89.76M | 86.63M |
| EBITDA | 173.33M | 96.85M | 79.98M | 119.87M | 101.87M |
| EBITDA Margin | 15.3% | 7.5% | 7.0% | 10.8% | 8.6% |
| Operating Income | 89.51M | (2.32M) | (19.33M) | 337K | 11.67M |
| Operating Margin | 7.9% | -0.2% | -1.7% | 0.0% | 1.0% |
| Interest Income | 0 | 0 | 14.76M | 24.9M | 11.9M |
| Interest Expense | 22.39M | 130K | 0 | 4.53M | 3.91M |
| Other Income / Expenses | (23.5M) | (130K) | (779K) | 25.26M | (340K) |
| Income Before Tax | 66.01M | (2.45M) | (20.11M) | 25.59M | 11.33M |
| Pre-Tax Margin | 5.8% | -0.2% | -1.8% | 2.3% | 1.0% |
| Income Tax Expense | (11.84M) | (8.1M) | 263K | 13.06M | 9.27M |
| Net Income | 77.85M | 5.65M | (20.37M) | 12.53M | 2.05M |
| Net Margin | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
| EPS (Basic) | 1.79 | 0.13 | (0.45) | 0.27 | 0.04 |
| EPS (Diluted) | 1.62 | 0.12 | (0.45) | 0.27 | 0.04 |
| Weighted Avg Shares | 43.48M | 44.4M | 45.21M | 46.05M | 45.97M |
| Weighted Avg Shares (Diluted) | 47.94M | 45.89M | 45.21M | 46.26M | 46.36M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.